Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NASDAQ:INSM NASDAQ:LEGN NASDAQ:ONC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$109.75-1.1%$103.56$76.53▼$131.49$26.38B1.29939,004 shs286,100 shsINSMInsmed$102.92+1.0%$83.40$60.40▼$106.83$19.55B0.92.29 million shs1.93 million shsLEGNLegend Biotech$39.07-0.9%$33.08$27.34▼$60.87$7.20B0.191.37 million shs1.19 million shsONCBeOne Medicines$268.09+6.3%$247.15$146.87▼$287.88$29.38B0.28431,999 shs403,366 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech-1.67%+0.86%+4.16%+12.12%+30.67%INSMInsmed+3.78%+5.10%+3.20%+43.37%+32.82%LEGNLegend Biotech+1.23%+9.95%+7.09%+16.89%-27.46%ONCBeOne Medicines+0.74%+4.63%-6.49%+5.57%+25,213,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNTXBioNTech2.5315 of 5 stars4.42.00.00.02.20.80.0INSMInsmed4.0819 of 5 stars2.54.00.04.33.41.70.6LEGNLegend Biotech3.4047 of 5 stars4.53.00.00.02.11.70.6ONCBeOne Medicines2.5068 of 5 stars3.50.00.00.03.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.83Moderate Buy$137.9125.67% UpsideINSMInsmed 3.00Buy$108.075.00% UpsideLEGNLegend Biotech 2.90Moderate Buy$73.3387.70% UpsideONCBeOne Medicines 3.00Buy$320.6719.61% UpsideCurrent Analyst Ratings BreakdownLatest LEGN, ONC, BNTX, and INSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025LEGNLegend BiotechMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$80.00 ➝ $81.007/10/2025BNTXBioNTechMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$132.00 ➝ $133.007/8/2025INSMInsmedJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$90.00 ➝ $111.007/8/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.007/2/2025LEGNLegend BiotechUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$60.00 ➝ $54.006/27/2025ONCBeOne MedicinesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$313.00 ➝ $330.006/27/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$317.00 ➝ $321.006/27/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$311.006/25/2025BNTXBioNTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$138.006/16/2025BNTXBioNTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$145.00 ➝ $138.006/11/2025INSMInsmedThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$100.00 ➝ $112.00(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$2.98B8.86N/AN/A$87.61 per share1.25INSMInsmed$381.03M51.24N/AN/A$1.60 per share64.32LEGNLegend Biotech$627.24M11.45N/AN/A$5.70 per share6.85ONCBeOne Medicines$3.81B7.71N/AN/A$34.10 per share7.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$719.92M-$3.40N/AN/AN/A-27.37%-3.94%-3.41%8/4/2025 (Estimated)INSMInsmed-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/6/2025 (Estimated)LEGNLegend Biotech-$177.03M-$0.59N/AN/AN/A-29.95%-21.19%-13.47%8/8/2025 (Estimated)ONCBeOne Medicines-$644.79M-$3.72N/A377.59N/A-9.40%-7.55%-4.42%N/ALatest LEGN, ONC, BNTX, and INSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025LEGNLegend Biotech-$0.18N/AN/AN/A$237.49 millionN/A8/4/2025Q2 2025BNTXBioNTech-$1.38N/AN/AN/A$161.26 millionN/A5/13/2025Q1 2025LEGNLegend Biotech-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 million5/8/2025Q1 2025INSMInsmed-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million5/7/2025Q1 2025ONCBeOne Medicines-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTechN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.0110.1810.02INSMInsmed11.385.865.44LEGNLegend Biotech0.305.205.07ONCBeOne Medicines0.051.961.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%INSMInsmedN/ALEGNLegend Biotech70.89%ONCBeOne Medicines48.55%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%INSMInsmed3.00%LEGNLegend Biotech0.02%ONCBeOne Medicines6.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech6,772240.39 million194.24 millionOptionableINSMInsmed1,271189.71 million184.02 millionOptionableLEGNLegend Biotech2,609183.76 million183.73 millionOptionableONCBeOne Medicines11,000109.60 million102.34 millionN/ALEGN, ONC, BNTX, and INSM HeadlinesRecent News About These CompaniesBeOne Medicines (NASDAQ:ONC) Shares Gap Up - Here's Why2 hours ago | marketbeat.comBeOne Medicines (NASDAQ:ONC) Rating Lowered to Hold at Wall Street ZenJuly 14 at 2:01 AM | americanbankingnews.comBiocytogen Enters into Antibody Licensing Agreement with BeOne ...July 13 at 2:46 PM | businesswire.comBeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) CEO John Oyler Sells 27,802 SharesJuly 12 at 6:12 AM | insidertrades.comBeOne Medicines (NASDAQ:ONC) Cut to Hold at Wall Street ZenJuly 12 at 2:55 AM | marketbeat.comBeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) CEO Sells $7,044,470.76 in StockJuly 11, 2025 | marketbeat.comBeOne Medicines Ltd. American Depositary Shares (ONC) Insider ActivityJuly 11, 2025 | nasdaq.comBrokerages Set BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Price Target at $320.67July 11, 2025 | americanbankingnews.comBiocytogen inks antibody deal with BeOne, expanding strategic tiesJuly 10, 2025 | thepharmaletter.comTEuropean Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal CarcinomaJuly 10, 2025 | ncnewsonline.comNNICE moves fast on Brukinsa in MCLJuly 10, 2025 | thepharmaletter.comTEuropean Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal CarcinomaJuly 10, 2025 | businesswire.comNICE backs new drugs for Crohn's disease, lymphomaJuly 10, 2025 | pharmaphorum.comPBiocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug DevelopmentJuly 9, 2025 | businesswire.comBiocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug DevelopmentJuly 9, 2025 | businesswire.comONC BeOne Medicines Ltd. - Seeking AlphaJuly 8, 2025 | seekingalpha.comBeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Receives Consensus Rating of "Buy" from BrokeragesJuly 8, 2025 | marketbeat.comThis Startup Built A Hospital In India To Test Its AI SoftwareJuly 2, 2025 | forbes.comBeOne Medicines showcases oncology pipelineJune 27, 2025 | thepharmaletter.comTBeOne Medicines (NASDAQ:ONC) Shares Gap Down - Time to Sell?June 27, 2025 | marketbeat.comMorgan Stanley Forecasts Strong Price Appreciation for BeOne Medicines (NASDAQ:ONC) StockJune 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Is Rising Again Despite Dilution—What’s the Deal?By Nathan Reiff | July 7, 2025View D-Wave Is Rising Again Despite Dilution—What’s the Deal?These 3 Dividend Stocks Are Not Concerned With Tariff NoiseBy Thomas Hughes | July 11, 2025View These 3 Dividend Stocks Are Not Concerned With Tariff NoisePalantir Gets Price Hike From Wedbush Amid High ValuationBy Chris Markoch | July 15, 2025View Palantir Gets Price Hike From Wedbush Amid High ValuationIGM ETF: Expand Tech Exposure With Top AI LeadersBy Jeffrey Neal Johnson | July 1, 2025View IGM ETF: Expand Tech Exposure With Top AI LeadersMarketBeat Week in Review – 07/07 - 07/11By MarketBeat Staff | July 12, 2025View MarketBeat Week in Review – 07/07 - 07/11LEGN, ONC, BNTX, and INSM Company DescriptionsBioNTech NASDAQ:BNTX$109.74 -1.26 (-1.13%) As of 02:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Insmed NASDAQ:INSM$102.92 +1.03 (+1.01%) As of 02:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Legend Biotech NASDAQ:LEGN$39.07 -0.37 (-0.94%) As of 02:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.BeOne Medicines NASDAQ:ONC$268.09 +15.95 (+6.33%) As of 02:22 PM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Analysts Set $600 Target Ahead of Microsoft Earnings NVDA Greenlight: China H20 Sales Spark 50% Rally Potential New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Insider Selling Hits Market Leaders—Should You Be Worried? MP Materials Stock Booms on New Government Positioning Tilray Shares Blazing: What's Behind the 55% Rally This Month? Will Dollar Tree Break Out After a New $2.5 Billion Buyback? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
